Bristol-Myers Squibb Co. sought to convince investors Thursday that its future was bright despite a major cancer drug setback by unveiling an organizational revamp and $3 billion share buyback while reporting better-than-expected quarterly results. Shares in the New York-based drug company lost as much as a third of their value after it announced in August that immunotherapy Opdivo failed to meet the main goal of a critical study...

Source: Wall Street Journal October 27, 2016 11:39 UTC